Cargando…
Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go?
The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis factor (TNF)-blocking drugs and methotrexate produces...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206357/ https://www.ncbi.nlm.nih.gov/pubmed/17540047 http://dx.doi.org/10.1186/ar2177 |
_version_ | 1782148452799479808 |
---|---|
author | Ikeda, Kei Cox, Sally Emery, Paul |
author_facet | Ikeda, Kei Cox, Sally Emery, Paul |
author_sort | Ikeda, Kei |
collection | PubMed |
description | The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis factor (TNF)-blocking drugs and methotrexate produces superior outcomes over monotherapy alone; however, use is limited by cost and potential side-effects. Currently, anti-TNF therapy is normally reserved for patients who have failed traditional disease-modifying anti-rheumatic drugs. The question that remains is whether TNF-blocking drugs are better used if given early; the high direct costs are countered by both direct and indirect savings in healthcare costs from optimal control of disease, and the benefits of early control outweigh the increased risk of infection and malignancy. |
format | Text |
id | pubmed-2206357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22063572008-01-19 Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? Ikeda, Kei Cox, Sally Emery, Paul Arthritis Res Ther Review The availability of newer, and more expensive, therapies for patients with rheumatoid arthritis has changed treatment beyond recognition. Disease remission is the goal for all new patients. Studies have shown that a combination of tumour necrosis factor (TNF)-blocking drugs and methotrexate produces superior outcomes over monotherapy alone; however, use is limited by cost and potential side-effects. Currently, anti-TNF therapy is normally reserved for patients who have failed traditional disease-modifying anti-rheumatic drugs. The question that remains is whether TNF-blocking drugs are better used if given early; the high direct costs are countered by both direct and indirect savings in healthcare costs from optimal control of disease, and the benefits of early control outweigh the increased risk of infection and malignancy. BioMed Central 2007 2007-05-24 /pmc/articles/PMC2206357/ /pubmed/17540047 http://dx.doi.org/10.1186/ar2177 Text en Copyright © 2007 BioMed Central Ltd |
spellingShingle | Review Ikeda, Kei Cox, Sally Emery, Paul Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? |
title | Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? |
title_full | Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? |
title_fullStr | Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? |
title_full_unstemmed | Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? |
title_short | Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go? |
title_sort | aspects of early arthritis. biological therapy in early arthritis – overtreatment or the way to go? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206357/ https://www.ncbi.nlm.nih.gov/pubmed/17540047 http://dx.doi.org/10.1186/ar2177 |
work_keys_str_mv | AT ikedakei aspectsofearlyarthritisbiologicaltherapyinearlyarthritisovertreatmentorthewaytogo AT coxsally aspectsofearlyarthritisbiologicaltherapyinearlyarthritisovertreatmentorthewaytogo AT emerypaul aspectsofearlyarthritisbiologicaltherapyinearlyarthritisovertreatmentorthewaytogo |